ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 26, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
October 05, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
September 13, 2021 08:30 ET
|
ABVC BioPharma, Inc.
Completion of the Study Expected by the End of 2022 FREMONT, CA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
ABVC BioPharma Provides Vitargus® Update
August 26, 2021 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
March 04, 2020 09:00 ET
|
American BriVision Holding Corporation
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) First of six patients has...
American BriVision Provides Corporate Update
February 28, 2020 09:00 ET
|
American BriVision Holding Corporation
FREMONT, CA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), an emerging clinical stage biopharmaceutical company focused on...
American BriVision Announces Postponement of Proposed Public Offering
February 25, 2020 12:57 ET
|
American BriVision Holding Corporation
Company Expects to Begin Licensing Vitargus to Marketing Partners in 2020 FREMONT, CA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB:...
American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
December 05, 2019 08:31 ET
|
American BriVision Holding Corporation
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) Phase II Part I trial of...
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
November 14, 2019 13:22 ET
|
American BriVision Holding Corporation
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...
American BriVision Appoints Chihliang "Andy" An as New Chief Financial Officer
October 08, 2019 10:06 ET
|
American BriVision Holding Corporation
FREMONT, CA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing...